Kangfang Bio（09926）在2024年12月31日完成了该年度的年度绩效，收入为21.24亿元人民币（下面均为INMB）；商业销售收入为204.4亿元人民币，同比增长25.34％；毛利润为183.5亿元人民币。 该公告表示，到目前为止，该公司正在开发50多个创新项目，涵盖了许多领域，例如肿瘤，自身免疫性和代谢疾病。其中，有61种独立开发的产品被批准用于营销，其中2种产品正在NMPA市场审查中。在临床III期中，共有12种产品进行了注册测试，而12个产品在I/II期的临床测试阶段处于临床测试阶段。 Among the pipeline products, 15 are the world's first-class first-in-class or best-to-class dual-anti-san-double-santi-retin-anti-anti-anti-sanctalTi-Ti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-sanities --It-retinator-anti-anti-anti-anti-anti-anti-anti-anti-anti-sanities-retinactivity-anti-anti-anti-anti-anti-sanities-sanctal --It-retinator-anti-anti-anti-anti-anti-anti-anti-anti-anti-sanities-retinactivity-anti-anti-anti-anti-anti-sanities-sanctal The company hopes to become a leading biopharmaceutical company通过出色和创新的研发，劳动和商业化平台。 金融的官方帐户 24小时广播滚动滚动最新的财务和视频信息，并扫描QR码，以获取更多粉丝效仿的好处（Sinafinance）